Enorama Pharma AB (publ) (STO:ERMA)
Sweden · Delayed Price · Currency is SEK 0.7060
+0.0060 (0.86%)
Sep 4, 2026, 9:22 AM CET
Enorama Pharma AB Revenue
Enorama Pharma AB had revenue of -34.00K SEK in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 1.77M, down -83.60% year-over-year. In the year 2025, Enorama Pharma AB had annual revenue of -6.74M.
Revenue (ttm)
1.77M
Revenue Growth
-83.60%
P/S Ratio
36.08
Revenue / Employee
361.75K
Employees
4
Market Cap
52.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | -6.74M | -34.35M | - |
| Dec 31, 2024 | 27.61M | 26.49M | 2,363.16% |
| Dec 31, 2023 | 1.12M | -8.32M | -88.13% |
| Dec 31, 2022 | 9.44M | -3.50M | -27.06% |
| Dec 31, 2021 | 12.95M | 7.83M | 152.77% |
| Dec 31, 2020 | 5.12M | -5.41M | -51.38% |
| Dec 31, 2019 | 10.54M | -1.55M | -12.83% |
| Dec 31, 2018 | 12.09M | 10.09M | 506.07% |
| Dec 31, 2015 | 1.99M | 611.00K | 44.18% |
| Dec 31, 2014 | 1.38M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Newbury Pharmaceuticals AB | 35.02M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
| Dicot Pharma AB | 200.00K |
Enorama Pharma AB News
- 16 days ago - Enorama Records Lower Q2 Loss With Pending PMTA Case; Stock Down - Nasdaq
- 16 days ago - Enorama Pharma AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Enorama Pharma AB Quarterly report: Q1 2026 - Filings
- 5 months ago - Enorama Pharma AB Quarterly report: Q4 2025 - Filings
- 5 months ago - Enorama Pharma AB Annual report: Q4 2025 - Filings
- 9 months ago - Enorama Pharma AB Quarterly report: Q3 2025 - Filings